Instrument Inactif

Communiqués Genmab Nasdaq Copenhagen

Actions

DK0010272202

Recherche biotechnologique et médicale

Temps réel estimé Cboe Europe Autres places de cotation 17:00:45 24/07/2026			Varia. 5j.	Varia. 1 janv.
1 878,50 ^DKK	+54,35%		+4,14%	+14,24%

06:50	Actions nordiques en Amérique du Nord - Ericsson recule de 0,7 %	FW
23/07	Genmab A/S et AbbVie apportent des précisions sur l'essai de phase 3 EPCORE DLBCL-1 évaluant l'epcoritamab (DuoBody-CD3xCD20) chez des patients atteints d'un lymphome diffus à grandes cellules B (LDGCB) en rechute ou réfractaire	CI

Communiqués

23/07	Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	GL
15/07	Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026	GL
06/07	Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma	GL
06/07	Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma	BU
29/06	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival	BU
29/06	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival	GL
17/06	Genmab A/S : has published its Articles of Association	PU
16/06	Capital Increase in Genmab as a Result of Employee Warrant Exercise	GL
16/06	Capital Increase in Genmab as a Result of Employee Warrant Exercise	AQ
15/06	Major Shareholder Announcement	GL
15/06	Major Shareholder Announcement	AQ
15/06	Genmab A/S : has published its Articles of Association	PU
13/06	Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)	BU
13/06	Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)	GL
11/06	Grant of Restricted Stock Units and Warrants to Employees in Genmab	GL
11/06	Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients	BU
11/06	Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients	GL
29/05	Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons	GL
22/05	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology Annual Meeting and the European Hematology Association 2026 Congress	AQ
21/05	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress	BU
21/05	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress	GL
13/05	Genmab A/S : Articles of association dated May 12, 2026 – English	PU
13/05	Genmab A/S : has published its Articles of Association	PU
12/05	Capital Increase in Genmab as a Result of Employee Warrant Exercise	GL
11/05	Genmab - Major Shareholder Announcement	AQ